REGN

Regeneron Stock Soars 13%: Revenue Jumps 36% as Dupixent Hits a Record

2026-10-30

Regeneron Pharmaceuticals (NASDAQ: REGN) stock soared on Friday, October 30, 2026, after the biotech reported third-quarter revenue up 36% to $5.12 billion and non-GAAP earnings of $20.07 per share...